logo
  

CHMP Adopts Positive Opinion For Deciphera's Qinlock To Treat Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.

The European Commission decision is anticipated by the fourth quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
HSBC Holdings Plc shares were gaining In London trading as well as in pre-market activity on the NYSE after the Asia-focused lender backed its positive outlook after reporting significantly higher third-quarter profit. Further, the company announced share buyback of $2 billion, which will be commenced shortly. Walmart is recalling certain Aromatherapy Room Spray due to the possible presence of a rare and dangerous bacteria that is suspected to be behind two deaths in the United States, the U.S. Consumer Product Safety Commission said. The recall involves about 3,900 bottles of Better Homes and Gardens-branded Essential Oil Infused Aromatherapy Room Spray with Gemstones in six different scents. Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port.
Follow RTT